Higher Baseline Vitamin D Levels Enhance Semaglutide's Glycemic and Weight Loss Effects in Type 2 Diabetes

Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to hyperglycemia. Current treatments often aim for glycemic control and weight management. Semaglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist, is a highly effective therapy for T2D, known for its robust effects on both blood glucose and body weight. However, individual responses vary. Vitamin D has been increasingly recognized for its role beyond bone health, with implications in metabolic regulation, including insulin sensitivity and inflammation. The specific interplay between baseline vitamin D status and the efficacy of GLP-1R agonists like semaglutide in T2D patients has remained an important area of investigation.

This study retrospectively analyzed outcomes in patients with type 2 diabetes who were treated with semaglutide. Patients were categorized into three groups based on their baseline 25(OH)D levels: less than 15 ng/mL, 15-25 ng/mL, and greater than 25 ng/mL. The researchers compared the changes in primary endpoints, specifically HbA1c and BMI, across these vitamin D status groups. The analysis aimed to determine if baseline vitamin D levels were associated with the magnitude of glycemic and weight loss responses to semaglutide therapy.

Patients with higher baseline vitamin D levels demonstrated significantly improved outcomes when treated with semaglutide. Compared to those with 25(OH)D levels less than 15 ng/mL, patients in the 15-25 ng/mL group showed greater reductions in HbA1c [β = -0.083, 95% CI (-0.154 to -0.013), p = 0.020]. Even more pronounced reductions in HbA1c were observed in patients with levels greater than 25 ng/mL [β = -0.096, 95% CI (-0.173 to -0.017), p = 0.016].

Patients with 25(OH)D levels between 15-25 ng/mL and greater than 25 ng/mL also exhibited greater reductions in BMI [β = -1.02, 95% CI (-1.46 to -0.58) for the 15-25 ng/mL group, with the p-value for BMI not provided in the abstract snippet]. These findings suggest a dose-response relationship where increasing baseline vitamin D status correlates with enhanced therapeutic efficacy of semaglutide.